丽珠胃三联加达克普隆根除幽门螺杆菌(HP)疗效观察

观察丽珠胃三联加达克普隆根除HP疗效，探索根除HP最佳方案。方法 将190例HP感染患者分为两组，观察组94例给丽珠胃三联4片（2次／日）＋达克普隆30mg（1次／日）；对照组96例给丽珠得乐0．22g＋阿莫西林1．0g＋瑞贝克80mg＋雷尼替丁0．15g，2次／日；两组疗程均7天。停药1个月复查尿素酶试验及病理切片两者均阴性称根除。无效者互换治疗方案。结果：观察总组共123例，根除112例，根除率91．06％； 对照总组共105例，根除74例，根除率70．48％；未发现严重药物副作用，两组比较有显著差异（P＜0．01）。两组一般副作用分别为14．63％和15．2％，两组比较无显著性差异。结论 丽珠胃三联加达克普隆1周疗法根除HP疗效高，疗程短，无严重14．63％和15．2％，两组比较无显著性差异。结论 丽珠胃三联加达克普隆1周疗法根除HP疗效高，疗程短，无严重副作用，依从性好，值得经济条件好的地区作为首选方案；主张联合用药根除HP，避免选用患者可能耐药的抗菌素。     

使用洛活喜和洛汀新治疗160例高血压疗效观察

目的 观察丽珠胃三联加达克普隆根除HP疗效，探索根除HP最佳方案。方法 将190例HP感染患者分为两组，观察组94例给丽珠胃三联4片（2次／日）＋达克普隆30mg（1次／日）；对照组96例给丽珠得乐0．22g＋阿莫西林1．0g＋瑞贝克80mg＋雷尼替丁0．15g，2次／日；两组疗程均7天。停药1个月后复查尿酶试验及病理切片两者均阴性称根除。无效者互换治疗方案。结果：观察总组共123例，根除112例，根除率91．06％；对照总组共105例，根除74例，根除率70．48％；未发现严重药物副作用，两组比较有显著差异（P＜0．01）。两组一般副作用分别为14．63％和15．2％，两组比较无显著性差异。结论 丽珠胃三联加达克普隆1周疗法根除HP疗效高，疗程短，无严重副作用，依从性好，值得经济条件好的地区作为首选方案；主张联合用药根除HP，避免选用患者可能耐药的抗菌素。     

国产奥美拉唑四联疗法治疗消化性溃疡的疗效和成本—效果分析

目的：比较国产和合资产奥美拉唑对消化性消化性溃疡的疗效。安全性，成本－效果比。方法：将122例消化性溃疡病人随机分为治疗组和对照组。分别给予国产和合资产奥美拉唑（金奥康和洛赛克）40mg、日一次，两组同用丽珠胃三联，疗程一周，结果：一周溃疡愈合率分别为94．74％和96．55％，两组无显著性差异（P＞0．05）；不良反应少，两组无显著性差异（P＞0．05），且停用丽珠胃三联后不良反应消失；两组成本－效果比分别是1．03和2．38，有显著性差异（P＜0．05）。结论：金奥康和洛赛克在消化性溃疡的治疗上疗效，安全性相似，但金奥康的成本明显低于洛赛克。     

丽珠胃三联治疗肝硬化合并幽门螺杆菌感染性十二指肠球部溃疡的临床观察

目的：探讨丽珠胃三联治疗肝硬化患者合并幽门螺杆菌(Helicobacter pylori,Hp)感染性十二指肠球部溃疡的疗效及副作用。方法：48例肝硬化患者经胃镜确诊为十二指肠球部溃疡，同时经胃粘膜组织检测Hp阳性，应用丽珠胃三联治疗1周。结果：Hp根除率为91．7％，溃疡愈合率为75．0％，总有效率为95．8％，治疗前后血象、肝肾功能均无明显差异(P＞0．05)。结论；丽珠胃三联是经济、方便、高效的抗Hp方案，依从性好，适用于肝硬化合并幽门螺杆菌感染性十二指肠球部溃疡患者。     

奥美拉唑三联疗法根除幽门螺杆菌的疗效分析

目的比较奥美拉唑三联疗法与枸橼酸铋钾（cBs）三联疗法在消化性渍疡中对幽门螺杆菌（HP）的根除效果：方法将胃镜证实的HP阳性胃溃疡患者90例随机均分为治疗组（奥美拉唑三联疗法）和对照组（CBS三联疗法），疗程1周，疗程结束后1月复查HP。结果治疗组和对照组的HP根除率分别为93．33％（42／45）和88．89％（40／45），两组比较无显著性差异（P〉0．05）；渍疡愈合率分别为95．56％（43／45）和77．78％（35／45），两组比较有显著性差异（P〈0．05）。结论奥美拉唑三联疗法可以有效根除消化性溃疡患者的HP，促进溃疡愈合。     

丽珠胃三联加达克普隆根除幽门螺杆菌疗效观察

目的观察丽珠胃三联达克普隆根除HP疗效，探索根除HP最佳方案。方法将190例HP感染病人分为二组，观察组94例给丽珠胃三联4片2／日 达克普隆30md／日；对照组96例给丽珠得乐0．22 阿莫西林1．0 瑞贝克80mg 雷尼替丁0．152／日，疗程均7日。停药1月后复查尿素酶试验及病理切片两者均阴性称根除。无效者互换治疗方案，称复治观察组及复治对照组。结果观察组根除率92．6％，对照组根除率69．7％，无严重药物副作用。复治观察组根除率96．7％，复治对照组根除率57．1％。结论丽珠胃三联加达克普隆1周疗法根除HP疗效高，疗程短，无严重副作用，依从性好，值得经济条件好的地区作为首选方案；主张联合用药根除HP，避免选用患者可能耐药的抗生素。     

丽珠胃三联加达克普隆根除幽门螺杆菌(HP)疗效观察

将190例HP感染病人分为两组，观察组（1）94例给丽珠胃三联4片2／d 达克普隆30mg1/d，对照组（1）96例给丽珠得乐0．22＋阿莫西林1．0＋瑞贝克80mg 雷尼替丁0．152／d，疗程均7d，停药1月后复查尿素酶试验及病理切片两者均阴性称根除，根除失败者互换治疗方案称观察组（2）及对照组（2），结果表明观察总组共123例根除112例，根除率91．1％，对照总组共105例根除74例，根除率70．5％，无发现严重药物副作用，两组比较有显著差异（P＜0．01），两组一般副作用分别为14．6％和17．2％比较无差异。     

丽珠胃三联联合胃复春在HP阳性萎缩性胃炎治疗中的应用评价

目的：探讨HP阳性萎缩性胃炎行丽珠胃三联联合胃复春治疗的临床效果。方法：选取82例HP阳性萎缩性胃炎患者分为观察组与对照组各41例,对照组行丽珠胃三联治疗,观察组施加胃复春治疗,对比临床效果。结果：对照组治疗总有效率、HP根除率比较以及不良反应发生率分别为73.17%、68.29%、21.96%明显低于观察组的97.56%、95.12%、7.32%（P＜0.05）。结论：HP阳性萎缩性胃炎行丽珠胃三联联合胃复春治疗的效果显著,值得推广。     

两种三联用药治疗幽门螺杆菌感染的疗效比较

目的比较左氧氟沙星联合枸橼酸雷尼替丁、阿莫西林和左氧氟沙星联合质子泵抑制剂、阿莫西林两种三联用药治疗幽门螺杆菌感染的有效性和安全性。方法将66例HP阳性胃、十二指肠溃疡患者,随机分为观察组和对照组,每组33例。观察组给予枸橼酸铋雷尼替丁（400mg）＋左氧氟沙星（0．2g）＋阿莫西林（1．0g）,每日2次,口服;对照组给予泮托拉唑（40mg）＋左氧氟沙星（0．2g）＋N莫西林（1．0g）,每日2次,日服。疗程7d,观察两组HP根除率。结果观察组HP根除率为89．2％,溃疡愈合率为82．4％;对照组HP根除率为87％,溃疡愈合率为91．75％。两组比较,溃疡愈合率及HP根除率差异无统计学意义（P〉0．05）。结论左氧氟沙星联合枸橼酸雷尼替丁、阿莫西林和左氧氟沙星联合质子泵抑制剂、阿莫西林两种三联用药治疗HP感染根除率高．症状缓解快．不良反应少。     

雷贝拉唑治疗幽门螺杆菌阳性十二指肠溃疡的临床研究

目的观察雷贝拉唑联用抗生素治疗幽门螺杆菌（HP）阳性十二指肠溃疡的临床疗效。方法将80例患者随机分为治疗组（雷贝拉唑组）40例和（奥美拉唑组）40例，并同时加用阿莫西林和甲硝唑进行治疗，停药后4周复查胃镜及HP检测。结果治疗组疼痛消失时问（1．27±0．83）d短于对照组（2．41±1．26）d，差异具有显著性（P〈0．05）；1周末、2周末的症状消失率两组分别为95．0％（38／40）、97．5％（39／40）和90．0％（36／40）、95．0％（38／40），差异无显著性（均P〉0．05）；HP根除率分别为95．O％（38／40）和92．5％（37／40）（P〉0．05）；溃疡愈合率和总有效率分别为95．0％（38／40）、97．5％（39／40）和90．1％（38／42）、95．0％（38／40），两组比较差异无显著性（P〉0．05）；治疗组不良反应8例少于对照组14例。结论雷贝拉唑有较高的溃疡愈合率和HP根除率，止痛效应快，不良反应发生率较低。     

Does eradication of Helicobacter pylori alone heal duodenal ulcers?

BACKGROUND: Eradication of Helicobacter pylori infection prevents duodenal ulcer (DU) relapse, but it remains uncertain whether eradication of H. pylori alone heals duodenal ulceration. AIM: To test the hypothesis that eradication of H. pylori infection is accompanied by healing of duodenal ulcer. METHODS: A total of 115 consecutive patients with endoscopically confirmed H. pylori-infected duodenal ulcer were randomly assigned to one of two groups. Group BTC patients received a 1-week course of colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d. Group OBTC patients received omeprazole 20 mg daily for 4 weeks with the BTC regimen during the first week. Endoscopy with antral biopsies and 13C-urea breath test (UBT) were performed before and 4 weeks after completion of the 7-day triple or quadruple therapy. RESULTS: Eight patients dropped out (four in BTC and four in OBTC). Duodenal ulcer healing rates on an intention-to-treat basis in BTC and OBTC were 86% (95% CI: 77-95%) and 90% (95% CI: 82-98%), respectively. The eradication rates of H. pylori on an intention-to-treat basis in BTC and OBTC were 88% (95% CI: 79-96%) and 91% (95% CI: 84-99%), respectively. There were no statistically significant differences in ulcer healing rates and eradication rates between these two groups (P > 0.05). Epigastric pain resolved more rapidly in patients assigned to OBTC compared with those assigned to BTC. Both of the two regimens were well tolerated with only minor side-effects (3% of the 115 patients) and the compliance was good. CONCLUSIONS: BTC is a very effective H. pylori eradication regimen. Almost all duodenal ulcers heal spontaneously after cure of H. pylori infection using a 1-week low-dose bismuth-based triple therapy. Treating duodenal ulcer with simultaneous administration of omeprazole achieves ulcer pain relief more rapidly.     

埃索美拉唑短程三联疗法治疗老年消化性溃疡的临床观察

目的观察埃索美拉唑短程三联疗法对幽门螺杆菌(Hp)相关性老年消化性溃疡病的治疗效果。方法选取55例Hp阳性,年龄在60岁以上的消化性溃疡患者,随机分成两组。第1组:Hp阳性的十二指肠溃疡患者,第2组:Hp阳性的胃溃疡患者。分别予以埃索美拉唑20 mg,阿莫西林1 000 mg,呋喃唑酮100 mg,每日2次,疗程7 d。观察各组患者症状缓解情况,Hp根除率,不良反应及溃疡愈合率。结果各组患者症状在1~3d内缓解,Hp根除率第1组、第2组分别为91%、94%。溃疡愈合率分别为95%、91%。结论埃索美拉唑联合治疗老年性消化性溃疡1周方案,Hp根除率高,顺从性和耐受性好。     

Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study

BAKCGROUND: In Asian countries with limited resources, clarithromycin-based triple therapy may not be readily available. There are also few direct comparisons of different regimens in Asia. AIM: To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing. METHODS: Fourteen centres in Asia participated in this study. Patients with acute duodenal ulcer who were H. pylori-positive were recruited. They were randomized to receive: (a) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and metronidazole 500 mg b.d. for 2 weeks (LAM-2 W), or (b) LAM for 1 week and placebo (LAM-1 W), or (c) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks (LA-2 W). Upper endoscopy was repeated at week 6 to check for duodenal ulcer healing. Symptoms and side-effects were recorded. RESULTS: A total of 228 patients were recruited, and two patients took less than 50% of the drugs. H. pylori eradication rates (intention-to-treat) were 68 out of 82 (83%) with LAM-2 W, 55 out of 71 (78%) with LAM-1 W and 43 out of 75 (57%) with LA-2 W. There were significant differences (P=0. 001) in eradication rates when comparing either LAM-2 W or LAM-1 W with LA-2 W. The eradication rate in patients with metronidazole resistant H. pylori strains were significantly lower than those with metronidazole sensitive strains (P=0.0001). The duodenal ulcer healing rates at week 6 were 85%, 85% and 72% in LAM-2 W, LAM-1 W and LA-2 W, respectively (P=0.065). Side-effects occurred in 13%, 11% and 9% in LAM-2 W, LAM-1 W and LA-2 W, respectively. H. pylori eradication and initial ulcer size were factors affecting duodenal ulcer healing. CONCLUSIONS: This Asian multicentre study showed that 1-week lansoprazole-based triple therapy without clarithromycin has similar efficacy in H. pylori eradication and ulcer healing compared with a 2-week regimen. Both triple therapies were significantly better than dual therapy in H. pylori eradication. Therefore, 1-week lansoprazole-based triple therapy is as safe and effective as 2-week therapy in eradication of H. pylori infection and healing of duodenal ulcer in these Asian centres.     

Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori

BACKGROUND: Many dual and triple therapy treatment regimens have been proposed for the eradication of Helicobacter pylori. However, assessing the relative efficacy of these regimens is complicated by differences in study design, and few well-controlled comparative studies have been reported. METHODS: This multicentre, randomized, double-blind study involved 530 duodenal ulcer patients, of whom 520 had confirmed H. pylori infection. Patients received 14 days b.d. dual therapy of either ranitidine bismuth citrate (RBC) 400 mg or omeprazole 20 mg, both with clarithromycin 500 mg to eradicate H. pylori, followed by a further 14 days of treatment with RBC 400 mg b. d. or omeprazole 20 mg o.d. to facilitate ulcer healing. H. pylori eradication and ulcer healing were assessed at least 26 days after the end of treatment. Adverse events were recorded throughout the study. RESULTS: H. pylori was eradicated in 90% of patients who received RBC with clarithromycin and in 66% of patients who received omeprazole with clarithromycin (per protocol; P<0.001). intention-to-treat eradication rates were 77% and 60%, respectively (P<0.001). Ulcer healing rates were 97% in the RBC treatment group and 95% in the omeprazole treatment group. Only 3% and 1% of patients in the RBC and omeprazole treatment groups, respectively, were withdrawn due to adverse events. CONCLUSIONS: RBC with clarithromycin is a simple and highly effective dual therapy regimen for the eradication of H. pylori, and is significantly more effective than omeprazole with clarithromycin. Both treatment regimens are well tolerated and effectively heal duodenal ulcers.     

埃索美拉唑与奥美拉唑治疗消化性溃疡132例疗效观察

目的比较埃索美拉唑与奥美拉唑三联疗法治疗幽门螺杆菌(Helicobacter pylori,简称Hp)阳性消化性溃疡的效果。方法将确诊为Hp阳性消化性溃疡132例患者随机分为埃索美拉唑组和奥美拉唑组,每组66例。两组分别给予阿莫西林1g,1日2次,克拉霉素0.5g,1日2次,埃索美拉唑组加用埃索美拉唑20mg,1日2次,奥美拉唑组加用奥美拉唑20mg,1日2次。1周后两组分别单用埃索美拉唑20mg,1日1次,奥美拉唑20mg,1日1次,维持治疗3周。两组患者治疗前和治疗后检测Hp状况。结果埃索美拉唑组溃疡愈合率为94.0%,奥美拉唑组溃疡愈合率为90.9%;埃索美拉唑组Hp根除率为92.4%,奥美拉唑组Hp根除率为84.9%。两组比较溃疡愈合率及Hp根除率差异无统计学意义(P>0.05);第1天和第2天腹痛缓解率埃索美拉唑组为36.4%和60.6%,奥美拉唑组为16.7%和33.3%,两组比较差异有统计学意义(P<0.05)。结论埃索美拉唑、阿莫西林、克拉霉素三联疗法治疗Hp感染消化性溃疡优于奥美拉唑、阿莫西林、克拉霉素三联疗法,腹痛缓解较快。     

铝镁加混悬液联用埃索美拉唑治疗幽门螺杆菌阳性十二指肠溃疡的疗效观察

目的 观察铝镁加混悬液联用埃索美拉唑治疗幽门螺杆菌阳性十二指肠溃疡的临床疗效.方法 将幽门螺杆菌感染阳性的十二指肠溃疡患者124例随机分为两组：对照组用埃索美拉唑＋阿莫西林＋克拉霉素抗Hp治疗,7天后单用埃索美拉唑;治疗组用埃索美拉唑＋阿莫西林＋克拉霉素抗Hp治疗,7天后应用埃索美拉唑联合铝镁加混悬液;治疗4周后复查胃镜,观察十二指肠溃疡愈合情况,停药4周后复查14C呼气试验,比较两组患者溃疡愈合率、治疗有效率及Hp根除率.结果 对照组和治疗组溃疡愈合率分别为61.29％和66.13％,差异无统计学意义（P＞0.05）;对照组和治疗组溃疡有效率分别为82.26％和95.16％,差异有统计学意义（x 2=5.153,P＜0.05）;对照组和治疗组Hp清除率分别为82.26％和79.03％,差异无统计学意义（P＞0.05）.结论 铝镁加混悬液联用埃索美拉唑治疗幽门螺杆菌阳性十二指肠溃疡的疗效优于单用埃索美拉唑.     

丽珠胃三联短程治疗Hp感染PU疗效观察

目的：观察丽珠胃三联短程治疗Hp感染消化性溃疡（PU）1周的疗效。方法：观察了100例Hp感染的PU,其中,GU40例,DU60例。随机分成三组,A组丽珠胃三联治疗1周,B组丽珠胃三联治疗2周,C组奥美拉唑、甲硝唑、阿莫西林胶囊治疗1周。服药前及停药后4周内镜检查14C呼气试验阳性者为Hp感染,Hp（-）为Hp根除。结果：100例患者完成治疗后复查,总有效率分别为89.4%、86.6%、87.5%。消化性溃疡治疗总有效率分别为94.7%、96.7%、93.2%,P〉0.05,差异均无统计学意义。三组有轻微副反应但不影响治疗。结论：结果表明了丽珠胃三联根除Hp后,溃疡很快愈合勿需加用抑酸剂。说明丽珠胃三联1周治疗方案具有疗程短、剂量小、副反应小、疗效高的特点,是理想根除Hp、治愈溃疡及降低复发的方案。     

雷贝拉唑为主的四联疗法治疗Hp阳性消化性溃疡

目的研究含雷贝拉唑为主的四联疗法对幽门螺杆菌(Hp)阳性的消化性溃疡的治疗效果。方法选取幽门螺杆菌阳性的消化性溃疡患者76例,随机分为对照组及实验组:对照组使用雷贝拉唑+左氧氟沙星+阿莫西林,实验组除上述药物外加用果胶铋,疗程7d,之后抗溃疡治疗。观察Hp根除率、溃疡愈合率及不良反应。结果对照组Hp根除率为71.05%,实验组为92.10%,两组比较差异有统计学意义(P<0.05);对照组溃疡愈合率为92.11%,实验组为94.74%,两组比较差异无统计学意义(P>0.05)。结论雷贝拉唑为主的四联疗法对幽门螺杆菌阳性的消化性溃疡的治疗安全有效。     

雷尼替丁枸橼酸铋联合克拉霉素根除幽门螺杆菌疗效观察

目的 比较雷尼替丁枸橼酸铋联合克拉霉素与奥美拉唑、甲硝唑、克拉霉素两种疗法对幽门螺杆菌（Hp）的根除效果。方法 123例Hp阳性的消化性溃疡患者分为2组：A组62例，以雷尼替丁枸橼酸铋1片（含：雷尼替丁100mg，枸橼酸铋钾110mg）、克拉霉素250mg口服，2次／d，疗程7d；B组61例，以奥美拉唑20mg、克拉霉素250mg加甲硝唑400mg口服，2次／d，疗程7d。结果 A、B两组的Hp根除率分别为86．9％和85．2％，活动期溃疡愈合率分别为97．6％和100％，副反应发生率分别为6．6％和8．2％，两组间Hp根除率、活动期溃疡愈合率和副反应发生率差异均无显著性（均P〉0．05）。结论 雷尼替丁枸橼酸铋联合克拉霉素与奥美拉唑、甲硝唑、克拉霉素两种疗法疗效相当，而雷尼替丁枸橼酸铋联合克拉霉素因价廉、安全在临床上更为实用。     

Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy

BACKGROUND: Several studies have shown that Helicobacter pylori eradication rates with standard 7-day triple therapy are unsatisfactory. A novel 10-day sequential treatment regimen recently achieved a significantly higher eradication rate. To improve the pharmacotherapeutic cost, we evaluated whether an acceptable eradication rate could be achieved in peptic ulcer patients by halving the dose of clarithromycin. METHODS: In a prospective, open-label study, 152 duodenal ulcer patients with H. pylori infection, assessed by rapid urease test and histology, were enrolled. Patients were randomized to receive either a 10-day sequential treatment comprising rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for the remaining 5 days (high-dose therapy), or a similar schedule with the clarithromycin doses halved to 250 mg b.d. (low-dose therapy). No further antisecretory drugs were offered. Four to six weeks after therapy, H. pylori eradication and ulcer healing rates were assessed by endoscopy. RESULTS: Similar H. pylori eradication rates were observed following high- and low-dose regimens for both per protocol (97.3% vs. 95.9%; P = N.S.) and intention-to-treat (94.7% vs. 92.2%; P = N.S.) analyses. No major side-effects were reported. At repeat endoscopy, peptic ulcer healing was observed in 93% and 93% of patients following high- and low-dose therapy, respectively. CONCLUSION: The cheaper low-dose sequential regimen may be suggested for H. pylori eradication in duodenal ulcer patients, even without continued proton pump inhibitor therapy after eradication treatment.